Physician profile
Saulius J Skeivys
NPI 1619013463
$4,863.00
in general payments reported to CMS, 2019-2025
11 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $411 · 2021: $622 · 2022: $895 · 2023: $852 · 2024: $981 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,469.69 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,020.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $993.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $534.46 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $334.16 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $165.37 | 2022-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.48 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $85.14 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $79.62 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $42.09 | 2020-2021 | |
| Sanofi Pasteur INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saulius Skeivys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.